Self-injection of Sayana Press holds great promise for helping women overcome access barriers and increase their ability to manage their health. Results from a PATH-Ministry of Health study on self-injection in Uganda, newly available online through the journal Contraception, indicate that self-injection is feasible and highly acceptable among most study participants in Uganda.
In the study, 380...

As access to Sayana® Press (subcutaneous depot medroxyprogesterone acetate, or DMPA-SC in Uniject™) expands globally, PATH has monitored product consumption in four pilot introduction countries: Burkina Faso, Niger, Senegal, and Uganda. As the introduction phase draws to a close and all four countries move toward scale-up, they are transitioning Sayana Press consumption data collection into...

Self-injection of the contraceptive Sayana® Press is both feasible and highly acceptable among women participating in the first such research study conducted in sub-Saharan Africa, according to results published online by the journal Contraception.
Sayana Press is an all-in-one injectable contraceptive that puts control of women's health in their hands. It is a subcutaneous formulation of the...

Monitoring financing for contraceptive procurement, from commitment through spending, is crucial to ensuring contraceptive security. Building on the guide Enhancing Contraceptive Security through Better Financial Tracking, the USAID | DELIVER PROJECT developed the Financial Tracking Toolkit, an online toolkit to provide guidance and tools to in-country stakeholders for tracking contraceptive...